Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307567 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Lilly Kelemen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke University, Durham, NC, United States of America. Hauptthemen laut MEDLINE: Alzheimer Disease, Genetic Therapy, Qualitative Research. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Introduction
We aimed to understand clinician views regarding gene therapy as a future treatment for Alzheimer’s disease (AD) and potential barriers and facilitators to its use.
Methods
We interviewed ten clinicians who treat patients with AD. Clinicians helped design a semi-structured interview including the following domains: establishing understanding, cost/access, quality of life, and religion/spirituality. Transcripts were analyzed by a coding team using descriptive content analysis with inductive approach.
Results
Clinicians identified three main areas of concern: 1) potential clinician and patient understanding of gene therapy and Alzheimer’s disease 2) consideration of inequity (i.e., care access, disease awareness along with education level, family support, trust in care systems); and 3) considerations in decision-making (i.e., religious/spiritual beliefs and method of treatment delivery as a decision-making tools). Discussion and conclusion Findings highlight areas for knowledge-building for patients and clinicians alike. Clinicians must be aware of patient/family educational needs and gaps in their own clinical knowledge before engaging patients/families with new technology. Allowing time for questions is crucial to building rapport and trust.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Duke University, Durham, NC, United States of America.
- Sanford School of Public Policy, Duke University, Durham, NC, United States of America.
- Department of Neurology, School of Medicine, Duke University, Durham, NC, United States of America.
- Division of Geriatric Medicine, School of Medicine, Duke University, Durham, NC, United States of America.
ORCID-Profile: Lilly Kelemen, Zollie Yavarow, Nathan A Boucher
Zitieren
APA
Kelemen, L., Gupta, I., Yavarow, Z., Smith, S. I., Johnson, K. G., & Boucher, N. A. (2024). Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study. PLOS ONE. https://doi.org/10.1371/journal.pone.0307567
Vancouver
Kelemen L, Gupta I, Yavarow Z, Smith SI, Johnson KG, Boucher NA. Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study. PLOS ONE. 2024. doi:10.1371/journal.pone.0307567
BibTeX
@article{Kelemen2024,
author = {Kelemen, Lilly and Gupta, Ishika and Yavarow, Zollie and Smith, Samantha I and Johnson, Kim G and Boucher, Nathan A},
title = {Clinician’s perspectives on gene therapy for Alzheimer’s disease: A qualitative study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307567}
}
EUVIMED